Profile data is unavailable for this security.
About the company
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.
- Revenue in EUR (TTM)--
- Net income in EUR--
- Incorporated--
- Employees3.19k
- LocationDiaSorin SpAvia Crescentino sncSALUGGIA 13040ItalyITA
- Phone+39 161487526
- Fax+39 161487670
- Websitehttps://www.diasorin.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ambu A/S | 722.95m | 31.51m | 3.59bn | 5.20k | 128.91 | 5.43 | 28.76 | 4.97 | 0.8839 | 0.8839 | 20.26 | 21.00 | 0.7694 | 2.21 | 7.14 | 1,037,529.00 | 3.35 | 3.22 | 3.91 | 3.87 | 59.38 | 59.54 | 4.36 | 4.43 | 1.47 | 58.64 | 0.0907 | 25.41 | 12.90 | 13.84 | 39.88 | -5.81 | 2.06 | 0.00 |
| Getinge AB | 2.92bn | 147.06m | 3.71bn | 11.85k | 27.06 | 1.51 | 11.61 | 1.27 | 6.21 | 6.21 | 123.33 | 111.09 | 0.5937 | 2.51 | 7.30 | 2,861,487.00 | 3.01 | 5.31 | 4.00 | 6.98 | 45.80 | 47.83 | 5.07 | 8.69 | 0.5965 | 10.34 | 0.2629 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| SCHOTT Pharma AG & Co KgaA | 948.56m | 150.41m | 4.01bn | 4.65k | 26.58 | 5.22 | 18.94 | 4.23 | 1.00 | 1.00 | 6.31 | 5.10 | 0.7434 | 4.34 | 4.07 | 204,166.20 | 11.82 | -- | 16.42 | -- | 34.18 | -- | 15.90 | -- | 1.06 | -- | 0.1086 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
| Sectra AB | 157.42m | 38.89m | 4.32bn | 1.22k | 118.74 | 32.09 | 90.87 | 27.46 | 2.31 | 2.31 | 9.36 | 8.55 | 0.6136 | -- | 3.63 | 1,503,436.00 | 15.16 | 15.75 | 28.08 | 29.52 | 47.01 | 64.95 | 24.71 | 19.59 | -- | -- | 0.027 | 0.00 | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| Carl Zeiss Meditec AG | 2.07bn | 203.20m | 4.96bn | 4.95k | 24.34 | -- | -- | 2.40 | 2.28 | 2.28 | 23.14 | -- | -- | -- | -- | 428,397.90 | -- | 9.56 | -- | 11.72 | 55.12 | 57.84 | 9.84 | 13.15 | -- | -- | -- | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
| Ypsomed Holding AG | 662.66m | 79.88m | 5.23bn | 2.60k | 65.52 | 7.84 | 32.29 | 7.90 | 5.45 | 5.45 | 45.20 | 45.56 | 0.5828 | 5.28 | 5.46 | 268,759.60 | 7.03 | 4.41 | 11.60 | 6.81 | 35.44 | 27.26 | 12.06 | 7.38 | 0.5060 | 13.12 | 0.3434 | 20.50 | 10.25 | 3.86 | 52.83 | 5.44 | 8.64 | 29.46 |
| Amplifon SpA | 2.36bn | 155.88m | 5.26bn | 14.38k | 33.69 | 4.69 | 11.69 | 2.23 | 0.6898 | 0.6898 | 10.40 | 4.96 | 0.6255 | 20.32 | 10.83 | 164,118.00 | 4.13 | 4.31 | 6.24 | 5.81 | 23.55 | 59.01 | 6.61 | 7.28 | 0.4043 | 5.23 | 0.6064 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| ConvaTec Group PLC | 2.11bn | 147.07m | 5.84bn | 10.13k | 39.82 | 3.68 | 16.37 | 2.76 | 0.0595 | 0.0595 | 0.8542 | 0.6443 | 0.5965 | 2.47 | 5.89 | 173,352.10 | 4.15 | 2.36 | 4.74 | 2.73 | 55.96 | 55.03 | 6.96 | 4.34 | 1.27 | 2.96 | 0.4604 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| DiaSorin SpA | -100.00bn | -100.00bn | 6.01bn | 3.19k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 10.30 | -- | 11.50 | -- | 66.70 | -- | 21.25 | -- | -- | -- | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| Demant A/S | 3.00bn | 355.10m | 7.89bn | 21.50k | 22.21 | 6.14 | -- | 2.63 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 1.07m | 1.91% |
| T. Rowe Price International Ltd.as of 30 Sep 2024 | 942.31k | 1.68% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 892.40k | 1.60% |
| Wellington Management Co. LLPas of 21 Nov 2024 | 821.63k | 1.47% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 774.64k | 1.39% |
| Invesco Advisers, Inc.as of 07 Nov 2024 | 713.15k | 1.28% |
| Shareholder Value Management AGas of 30 Apr 2024 | 499.10k | 0.89% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 440.93k | 0.79% |
| Financi�re de l'�chiquier SAas of 31 Mar 2024 | 422.15k | 0.76% |
| Impax Asset Management Ltd.as of 31 Oct 2024 | 313.35k | 0.56% |
